Vickers Venture Partners snags $285m for sixth fund

Its portfolio includes a firm working on a vaccine against COVID-19.

Singapore-based Vickers Venture Partners received commitments amounting to $285.48m (US$200m) for its target $713.69m (US$500m) Fund VI, according to a press release. This excludes general partner commitments.

The company aims it to be the largest non-government linked venture capital fund raised by a VC firm based in Southeast Asia.

Vickers’ portfolio so far comprises companies such as geothermal solutions startup Eavor, medtech decacorn Samumed and bioplastics firm RWDC Industries. It is also funding vaccine company Emergex, which is working on developing vaccinations against COVID-19.

Vickers Venture Partners is a venture capital firm focused on early-stage investments in Asia. The firm’s portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia